International Journal of Alzheimer’s Disease

Should CSF Biomarkers Support a Routine Analysis for Early Diagnosis of Alzheimer's Disease?


Publishing date
15 Sep 2010
Status
Published
Submission deadline
15 Mar 2010

1Centre for Memory Disturbances, Section of Neurology, University of Perugia, Italy

2Kliniken und Institut der Universität Duisburg-Essen, Germany

3Clinical Neurochemistry Laboratory, The Sahlgrenska Academy at Göteborg University, Mölndal, Sweden

4Department of Neurology, Clinical Research Centre, Mediteknia, University of Kuopio and Kuopio University Hospital, Finland


Should CSF Biomarkers Support a Routine Analysis for Early Diagnosis of Alzheimer's Disease?

Description

The degenerative process in AD probably begins 20–30 years before the first clinical symptoms become apparent; therefore, the possibility to discriminate individuals carrying incipient AD is utmost important, in view of the availability of drugs that may slow or even halt the progression of the disease. Two AD biomarkers extensively reported in literature are Aβ1-42 and isoforms of tau protein, which are the major components of brain senile plaques and neurofibrillary tangles. Levels of these proteins in cerebrospinal fluid (CSF) are commonly used both in Europe and in the United States for research and diagnostic purposes; the highest performance of these tests is for discriminating AD, even in early phases, from normal subjects. Up till now, thousands of subjects have been studied either in research or routine setting, giving sensitivity and specificity values invariably above 80%. Despite such results, CSF analysis is still considered only a supportive exam in AD diagnostic work-up. We think there is a great need to improve the medical awareness about the importance to perform lumbar puncture as a routine procedure in the diagnostic assessment of cognitive deterioration. Impressive data coming from recent large multicentre studies across several laboratories emphasize this need.

Before submission authors should carefully read over the journal's Author Guidelines, which are located at http://www.hindawi.com/journals/ijad/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/ according to the following timetable:


Articles

  • Special Issue
  • - Volume 2010
  • - Article ID 293587
  • - Editorial

Should CSF Biomarkers Support a Routine Analysis for Early Diagnosis of Alzheimer's Disease?

Lucilla Parnetti | Jens Wiltfang | Kaj Blennow
  • Special Issue
  • - Volume 2010
  • - Article ID 536538
  • - Review Article

Cerebrospinal Fluid Biomarkers for Dementia with Lewy Bodies

Elizabeta B. Mukaetova-Ladinska | Rachael Monteith | Elaine K. Perry
  • Special Issue
  • - Volume 2010
  • - Article ID 635053
  • - Research Article

Standardization of Assay Procedures for Analysis of the CSF Biomarkers Amyloid , Tau, and Phosphorylated Tau in Alzheimer's Disease: Report of an International Workshop

Charlotte E. Teunissen | Niek A. Verwey | ... | Marinus A. Blankenstein
  • Special Issue
  • - Volume 2010
  • - Article ID 548145
  • - Review Article

cNEUPRO: Novel Biomarkers for Neurodegenerative Diseases

Philipp Spitzer | Hans Wolfgang Klafki | ... | Jens Wiltfang
  • Special Issue
  • - Volume 2010
  • - Article ID 761571
  • - Research Article

Combined Analysis of CSF Tau, A 42, A 1–42% and A 1– % in Alzheimer's Disease, Dementia with Lewy Bodies and Parkinson's Disease Dementia

Mirko Bibl | Hermann Esselmann | ... | Brit Mollenhauer
  • Special Issue
  • - Volume 2010
  • - Article ID 959257
  • - Clinical Study

CSF Biomarkers Profile in CADASIL—A Model of Pure Vascular Dementia: Usefulness in Differential Diagnosis in the Dementia Disorder

Patrizia Formichi | Lucilla Parnetti | ... | Antonio Federico
  • Special Issue
  • - Volume 2010
  • - Article ID 417615
  • - Review Article

Are Guidelines Needed for the Diagnosis and Management of Incipient Alzheimer's Disease and Mild Cognitive Impairment?

Katie Palmer | Massimo Musicco | Carlo Caltagirone
  • Special Issue
  • - Volume 2010
  • - Article ID 978182
  • - Review Article

Biological Markers and Alzheimer Disease: A Canadian Perspective

Hyman M. Schipper
  • Special Issue
  • - Volume 2010
  • - Article ID 986310
  • - Research Article

Confounding Factors Influencing Amyloid Beta Concentration in Cerebrospinal Fluid

Maria Bjerke | Erik Portelius | ... | Kaj Blennow
  • Special Issue
  • - Volume 2010
  • - Article ID 610613
  • - Review Article

Lessons from Multicenter Studies on CSF Biomarkers for Alzheimer's Disease

Niklas Mattsson | Henrik Zetterberg | kaj Blennow
International Journal of Alzheimer’s Disease
 Journal metrics
Acceptance rate17%
Submission to final decision100 days
Acceptance to publication36 days
CiteScore3.800
Impact Factor-
 Submit

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.